1. The Nurse View

2. Introduction

3. Reasons for Lethality

4. Anatomy and Function of the Pancreas

5. Diagnosis

6. Role of CA 19-9

7. Staging

8. Risk Factors

9. Risk Factors (cont)

10. Risk Factors (cont)

11. Treatment of Metastatic Disease

12. Progress Depends on Clinical Trials

13. Top Recommendation: Clinical Trials

14. ACCORD 11: Pivotal Trial of FOLFIRINOX

15. MPACT: Pivotal Trial of nab-Paclitaxel Plus Gemcitabine

16. Most Common Hematologic Adverse Events

17. Treatment-Related Peripheral Neuropathy

18. Selection of First-Line Therapy

19. Choosing Chemotherapy for Metastatic Disease

20. Second-Line Nanoliposomal Irinotecan (MM-398): Study Design

21. Second-Line Nanoliposomal Irinotecan (MM-398): Efficacy Outcomes in NAPOLI-1

22. Second-Line Nanoliposomal Irinotecan (MM-398): Safety Outcomes in NAPOLI-1

23. Safety of Nanoliposomal Irinotecan in Practice

24. Educating Patients and Caregivers

25. Discussing Prognosis/End-of-Life Care

26. Educating Patients About Adverse Events

27. Patient Resources Online

28. Patient Resources Online (cont)

29. Pain Management in Pancreatic Cancer

30. Peripheral Neuropathy

31. Exocrine Pancreatic Insufficiency

32. Nausea

33. Conclusions

34. Abbreviations

35. Abbreviations (cont)